Cycurion shares tumble 18% on Nasdaq delisting notice
Cycurion, Inc. received a delisting determination from Nasdaq for failing to meet the $1.00 minimum bid price requirement for 31 consecutive business days. Following the news, shares dropped 18.36% in after-hours trading to $0.38. The company, which is ineligible for the standard 180-day compliance period due to a 1-for-30 reverse stock split in October 2025, intends to appeal the decision by July 17, 2026. While the appeal process stays the suspension, there is no guarantee of continued listing. Despite the regulatory challenge, the company reports an annual revenue run rate exceeding $28 million and maintains that operations remain unaffected.

*this image is generated using AI for illustrative purposes only.
Cycurion, Inc. shares fell 18.36% to $0.38 in after-hours trading Thursday after the cybersecurity company disclosed it received a delisting determination letter from The Nasdaq Stock Market LLC for failing to meet the minimum bid price requirement. The stock had closed the regular session up 2.04% at $0.47. The determination, dated July 10, 2026, states that the closing bid price of Cycurion’s common stock was below the $1.00 per share minimum for 31 consecutive business days from May 26, 2026, through July 9, 2026. Consequently, Nasdaq determined that the company does not comply with Nasdaq Listing Rule 5550(a)(1).
Because Cycurion effected a 1-for-30 reverse stock split on October 27, 2025, it is ineligible for the customary 180-calendar day compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv). Without a timely hearing request, trading was expected to be suspended at the opening of business on July 21, 2026. The company intends to file a hearing request before the July 17, 2026 deadline. A timely request will stay the suspension of Cycurion’s securities and the filing of a Form 25-NSE pending the Hearings Panel's decision. There is no assurance that the Hearings Panel will grant continued listing or that the company will regain compliance.
Trading Metrics and Strategic Status
Cycurion has a market capitalization of approximately $5.4 million, with a 52-week high of $16.03 and a 52-week low of $0.40. The stock has declined 95.97% over the past 12 months. Cycurion’s Board of Directors and management have determined not to pursue a reverse stock split at this time. The Board continues to evaluate all available options for regaining compliance, including actions related to the hearing process. The company emphasized that this matter does not impact its operations or strategic execution.
Kevin Kelly, Chairman and Chief Executive Officer of Cycurion, stated that the company is fully prepared for the Nasdaq Hearings Panel process. He noted that Cycurion is developing a data-driven record of trading activity supported by internal analysis and external market data to ensure the market valuation reflects underlying fundamentals.
Financial Metrics and Outlook
Cycurion reported that its business momentum remains strong, with an annual revenue run rate exceeding $28 million. This performance is supported by contracted backlog and a growing pipeline of opportunities, including recently secured multi-year agreements. The company continues to generate revenue growth through organic expansion, strategic acquisitions, and long-term customer contracts.
| Key Financial and Operational Details | |
|---|---|
| Annual Revenue Run Rate | Exceeding $28 million |
| Market Capitalization | Approximately $5.4 million |
| 52-Week High | $16.03 |
| 52-Week Low | $0.40 |
| Listing Rule Violation | Nasdaq Listing Rule 5550(a)(1) |
| Compliance Period Ineligibility | Nasdaq Listing Rule 5810(c)(3)(A)(iv) |
| Reverse Stock Split Date | October 27, 2025 |
| Hearing Request Deadline | July 17, 2026 |
Hearings are typically scheduled approximately 30 to 45 days following the company’s request. The Nasdaq Hearings Panel has broad discretion to consider all relevant factors in determining whether to grant continued listing or an extension. Cycurion is actively preparing its materials, including forensic analysis and engagement with external advisors, to support this process.
If the Nasdaq Hearings Panel denies continued listing, what alternative trading venues or over-the-counter markets might Cycurion utilize?
How will the company's inability to pursue another reverse stock split impact its strategy to regain the $1.00 minimum bid price?
What specific operational milestones or revenue targets must Cycurion hit to naturally lift its stock price without corporate actions?




























